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ABSTRACT 
Human gene therapy has faced many setbacks due to the immunogenicity and oncogenity of 
viruses. Safe and efficient alternative gene delivery vehicles are needed to implement gene 
therapy in clinical practice. Polymeric vectors are an attractive option due to their availability, 
simple chemistry, and low toxicity and immunogenicity. Our group has previously reported 
biodegradable polyethylenimines (PEI) that show high transfection efficiency and low toxicity by 
cross-linking 800 Da PEI with diacrylate cross-linkers using Michael addition. However, the 
synthesis was difficult to control, inconsistent, and resulted in polymers with a narrow range of 
molecular weights. In the present work, we utilized a heterogenous PVP(Fe(III)) catalyst to 
provide a more controllable PEI cross-linking reaction and wider range of biodegradable PEIs. 
The biodegradable PEIs reported here have molecular weights ranging from 1.2 kDa to 48 kDa, 
are nontoxic in MDA-MB-231 cells, and show low toxicity in HeLa cells. At their respective 
optimal polymer:DNA ratios, these biodegradable PEIs demonstrated about 2-5-fold higher 
transfection efficiency and 2-7-fold higher cellular uptake, compared unmodified 25 kDa PEI. 
The biodegradable PEIs show similar DNA condensation properties as unmodified PEI but more 
readily unpackage DNA, based on ethidium bromide exclusion and heparan sulfate competitive 
displacement assays, which could contribute to their improved transfection efficiency. Overall, 
the synthesis reported here provides a more robust, controlled reaction to produce cross-linked 
biodegradable PEIs that show enhanced gene delivery, low toxicity, and high cellular uptake 
and can potentially be used for future in vivo studies. 
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Chapter 1 
Introduction 
1.1  Gene Therapy in Medicine 
Gene therapy is a treatment of human disease through the transfer of genetic material into 
specific cells within a patient [1]. For example, a therapeutic gene may be inserted into the 
genome of the targeted cells to replace an errant gene [2]. This is a promising technique for 
curing diseases that are caused by genetic mutations, which can lead to malfunction or 
deficiency of proteins. The causes of some common diseases like hemophilia, cystic fibrosis, 
and severe combined immunodeficiency (SCID) are related to specific aberrant genetic 
mutations [3-5]. Gene therapies are also being studied for conditions that are not directly 
attributed to a defective gene, such as Alzheimer‟s disease, cardiovascular disease, and 
cancer. Such treatments involve inserting genes to increase the production of specific proteins, 
to change gene expression, or to kill disease-causing cells by producing cytotoxic growth factors 
or proteins [6-9]. By genetically modifying patients‟ cells to produce therapeutic proteins, gene 
therapy has the potential to eliminate some problems associated with therapeutic drug use, 
namely poor bioavailability, high cost, and the necessity for frequent doses [10].  
With the breakthrough of the Human Genome Project and the advancement of RNA and DNA 
technology, the particular human genes that correspond to different diseases or therapeutic 
protein production have been identified, and the promise of gene therapy has reached new 
heights. According to the National Institutes of Health, there are currently 1175 gene therapy 
clinical studies underway [11]. However, due to various limitations of delivering therapeutic RNA 
or DNA into target cells and/or tissues, gene therapy has yet to reach its full potential [12-13]. 
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Currently, the most challenging aspect of gene therapy is to deliver a therapeutic gene into 
target cells and/or tissues efficiently and without significant side effects. Most current gene 
delivery methods suffer some critical drawbacks that plague new therapies from getting past the 
clinical trial development phase [14-15]. Much research is needed to better understand the 
cellular dynamics of gene delivery, and to design molecularly and clinically effective gene 
therapy procedures. 
1.2  Ex Vivo Gene Therapy 
One common method for introducing therapeutic genetic material into patients is ex vivo gene 
therapy. Ex vivo gene delivery involves extracting autologous cells from the patient‟s body, 
inserting a therapeutic gene into the cells, and transplanting the autologous cells back into the 
patient. This technique is highly patient-specific and requires surgeries to remove and implant 
the cells back into the patient. Ex vivo gene therapy has been tested in clinical trials as a 
potential treatment for patients suffering from adenosine deaminase-deficient severe combined 
immunodeficiency (ADA-SCID). Patients with ADA-SCID suffer from the lack of production of 
adenonsine deaminase, an enzyme that is required to breakdown and salvage purine, causing 
an accumulation of lymphocyte-toxic deoxyadenosine [16]. As a result, the buildup of ADA 
substrates affects the development of T cells and ultimately leads to a severely compromised 
immune system [17]. In September 1990, ex vivo gene therapy was used for the first time to 
treat a 4 year old girl with ADA-SCID in National Institutes of Health. In this clinical trial, the 
patient‟s T cells were extracted and infected with a retrovirus modified to contain the gene that 
encodes for properly functional ADA. The infected cells were transplanted back to the patient, 
and transgene expression was monitored for 2 years. After the treatment, the in vivo expression 
of the functional ADA gene was detected in the patient, which suggested ex vivo gene therapy 
was a viable potential treatment for the ADA-SCID [18]. In a separate clinical test, three 
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newborns who suffered from ADA-SCID were treated with ex vivo gene delivery by extracting 
their umbilical cord blood cells and infecting the cells with a retrovirus-containing gene that 
encoded for functional ADA [19]. Even though the transgene expression of ADA was detected in 
the patients‟ bone marrow, only low percentages of circulating blood cells were found to carry 
the inserted functional ADA gene, not enough to obtain the targeted gene expression levels or 
therapeutic effect.  
Another somewhat successful clinical case using ex vivo gene therapy was the treatment of X-
linked severe combined immunodeficiency (X-SCID). X-SCID is caused by a genetic mutation in 
the gene IL2RG that codes for gamma chain protein in various interleukin receptors. The 
mutation disables the protein and receptors, which in turn prohibits the lymphocytes from 
differentiation and maturation, resulting in a severely weakened immune system [20]. Patients 
with X-SCID often suffer from infections like pneumonitis and moniliasis due to their 
compromised immune system. In 2000, ten infant boys with X-SCID were treated with ex vivo 
gene therapy by harvesting bone marrow from each patient and transducing the cells with 
recombinant retrovirus containing a gene encoding for functional -cytokine receptor. Out of the 
ten patients, nine were cured of X-SCID, restoring their immune system. However, three of 
these patients were later diagnosed with leukemia [21, 22]. It was discovered that the cancer 
was caused by mutation of the retroviral insertion, in which the retrovirus inserted the gene for -
cytokine receptor intro the patient‟s genome in the proximity of LMO2 proto-oncogene promoter 
and led to the transcription and expression of LMO2 [103] . These clinical cases show that gene 
therapy has great potential in curing genetic diseases, but at the same time, it also carries 
significant risks that must be eliminated for FDA-approval. 
1.3 In Vivo Gene Therapy 
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In vivo gene delivery involves direct injection of therapeutic genetic material using either viral or 
non-viral vectors to target specific cells in the patient‟s body. Compared to ex vivo delivery, in 
vivo delivery does not require surgery to extract diseased tissues and, more importantly, allows 
therapeutic genes to reach more transient targets like moving cells. An example of a disease 
treated using in vivo gene delivery is cystic fibrosis (CF). CF is an inherited genetic disease that 
affects the lungs and digestive system, causing difficulty in breathing, lung infection, and often 
early death. The cause of CF is a mutation in the gene that is responsible for the production of 
cystic fibrosis transmembrane conductance regulator (CFTR), a protein found in the epithelial 
cells of the lungs and pancreas [23]. The genetic mutation of CFTR affects the movement of 
chloride and sodium ions in and out of the cells, resulting in an imbalance of ion concentration in 
the body and the formation of a layer of thick mucus that blocks the airways and causes lung 
infections [24]. Research has shown that to prevent the development of CF, only 5-10% of the 
normal gene expression of CFTR is needed [25]. Because of the low therapeutic efficiency 
needed to treat CF, in vivo gene therapy has become an ideal treatment option. Several clinical 
studies have been conducted using both viral and non-viral in vivo gene therapy to treat CF [26]. 
Approximately one-third of the patients recovered ~20% ion concentration [27]. Although much 
research is needed to increase in vivo gene therapy‟s efficacy, the initial success of these trials 
shows the potential of in vivo gene therapy as a safe alternative technique to treat genetic 
diseases. 
Besides genetic diseases, another major potential treatment area for in vivo gene therapy is 
cancer. Currently, there are over 700 FDA-approved clinical trials using various in vivo gene 
therapies to treat tumors [28]. Cancer gene therapy can be summarized into 4 major 
approaches: 1) to replace the missing or altered gene that gives rise to cancer by substituting it 
with normal copies of the gene; 2) to activate the patient‟s immune system against cancer by 
inserting a gene that stimulates the patient‟s immune response; 3) to insert a gene into cancer 
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cells to make them more susceptible to radiation or chemotherapy; or 4) to induce the 
expression of a “suicide gene” in cancer cells that will trigger the patient‟s immune response 
against them [29]. Regardless of approach, there are some barriers that need to be overcome in 
order for in vivo gene therapy to be used for cancer treatment. Researchers need to ensure that 
the gene is carried specifically to the cancer cells (not the surrounding healthy cells), is inserted 
into the correct location in the genome, and does not cause any harmful mutations. 
1.4  Gene Delivery Methods 
The key component of most gene therapy is to alter the target cells to produce the therapeutic 
protein to treat the particular disease. In order for gene therapy to work properly, the gene 
encoding for the corresponding protein must be delivered into the target cells‟ nucleus for the 
gene to be transcribed and translated sufficiently. Two of the common physical methods used to 
directly inject DNA into a patient‟s cells are electroporation and gene gun. For electroporation, 
the target cells are exposed to intense electric pulses, where the cell membranes are disrupted 
and permeabilized, allowing DNA to transport into the cells [30]. This method generally 
damages a large number of target cells, which makes it a non-ideal technique for gene therapy, 
though recent research has shown that high voltage electroporation in pigs can destroy target 
cells while surrounding cells remain unaffected [31]. Gene guns basically utilize helium 
propellant to shoot DNA-loaded gold nanoparticles into target cells [32]. Though efficient for in 
vitro experiments, gene guns require large physical force to shoot the gene into tissues, often 
causing tissue damage and rendering the technique non-ideal for in vivo experiments. Due to 
the physical damage that both of the above methods cause, the more commonly researched 
gene delivery methods involve encapsulating the therapeutic DNA in viral vectors (adenovirus, 
retrovirus, etc.) or non-viral vectors (cationic polymers, lipids, etc.) to transport the DNA into the 
target cells [33-34].  
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1.5  Viral Gene Delivery Vectors 
A virus is a small infectious agent that is programmed to infect a living organism (the host) and 
hijack the host‟s cellular mechanisms to reproduce the virus molecule [35]. Generally, viruses 
consist of genetic material (DNA or RNA), a capsid protein coating that protects the genes, 
and/or a lipid envelope that protects the core when it is outside a cell. The two most common 
types of viruses used in gene therapy are retroviruses and adenoviruses. For retroviruses, the 
genetic material at the core is RNA, and the maximum size limit of the RNA is ~10 kbp. The 
capsid of a retrovirus is protected by a lipid envelope. The retrovirus, upon entering a host cell, 
reverse transcribes its RNA, integrates the corresponding DNA into the host‟s genome, and 
then replicates itself as part of the host‟s DNA. Unlike retroviruses, adenoviruses‟ genetic 
material is DNA, and the maximum size limit of the DNA is ~35 kbp. Adenoviruses are 
nonenveloped viruses, and its DNA is only delivered to the host‟s nucleus without incorporating 
into the host‟s genome. Adenoviruses are capable of infecting both dividing and non-dividing 
cells, while retroviruses can only infect dividing cells. 
Due to viruses‟ natural ability to transfer genes into cells, they have become an ideal candidate 
for gene delivery vectors. However, all the potentially infectious genes and immunogenic capsid 
proteins must be removed from the viruses before they can be used for gene therapy. Once 
these genes and proteins are removed, therapeutic genes can be inserted into the viruses‟ 
capsid, creating an extremely efficient virus-based therapeutic gene delivery carrier. 
Unfortunately, it is difficult to remove completely all the potentially harmful components of a 
virus, and those that may remain behind pose a serious pathogenic threat to the patient upon 
administration. Even though viruses show promise as an efficient gene delivery vehicle, they still 
suffer many drawbacks, namely oncogenicity, immunogenicity, and lack of cell targeting 
capability that hinder them from being FDA-approved as a viable therapy.  
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1.5.1 Immunogenicity 
As mentioned above, all viral genes and proteins must be completely removed in order for a 
virus to be used as a gene delivery vector. However, even if all viral components are extracted, 
a large dosage of viruses injected into a patient will still trigger the patient‟s immune system, 
resulting in either a serious immune response or greatly reduced gene delivery efficiency. The 
danger of fatal immune response caused by viral gene therapy was highlighted during a clinical 
trial in 1999 using an adenovirus as a delivery vector to treat ornithine transcarbamylase 
deficiency (OTCD) [36-37]. OTCD is a genetic disorder caused by the mutation of a gene that is 
normally responsible for the liver‟s production of ornithine transcarbamylase, an enzyme used to 
remove ammonia from the bloodstream. A large dose of adenovirus containing the therapeutic 
replacement gene was administered to the patient, causing an over-release of inflammatory 
cytokines and eventual systemic inflammatory response syndrome (SIRS). As a result of SIRS, 
the patient developed acute respiratory distress syndrome (ARDS), which proved fatal to the 
patient [38]. The death that occurred during this clinical trial led to a temporary suspension of all 
gene therapy trials by the FDA [39]. 
To prevent further immunogenicity-related deaths, researchers began to explore other types of 
viruses that possess less or no immunogenicity, such as adeno-associated viruses (AAVs). 
AAVs do not possess the pathogenicity associated with other types of viruses, and they 
currently have not been found to cause any human diseases [40]. AAVs are currently being 
tested in many clinical trials to treat various genetic diseases and prostate cancer [41]. There 
are a few limitations to using AAVs for gene therapy: 1) AAVs possess low cloning capability, 
making them difficult to mass produce, 2) AAVs have a small genome size (4.8kbp), which limits 
the type of therapeutic gene that could be inserted into the virus, and 3) AAV infection generally 
leads to an increase in antibody production, which could neutralize and reduce its efficacy [42-
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43]. Regardless of the type of virus used for gene therapy, even if the viral vectors do not trigger 
a fatal reaction, any human immune response will greatly reduce the efficiency of the viral 
delivery vector by either eliminating the viruses before infection or killing the infected cells 
before the inserted gene is expressed [44]. 
1.5.2 Oncogenicity 
One of the advantages of viral gene delivery is viruses‟ ability to carry genes efficiently into host 
cells. If the genetic cargo is inserted into the correct genomic location, viral gene therapy could 
provide the desired long-term therapeutic protein expression. However, if the gene is inserted 
randomly and disrupts normal gene expression or triggers an oncogene, cancer may develop as 
a result. Since adenoviruses do not insert their DNA into the host‟s genome, it is unlikely that 
adenoviruses will cause undesirable gene integration. AAVs do have the ability to integrate their 
DNA into the host‟s genome, but they primarily do so in a specific site on human chromosome 
19 [45-46]. Unlike adenoviruses and AAVs, retroviruses present the threat of undesired gene 
deletion or activation and genetic mutation due to random DNA integration into the host‟s 
genome. Cancer-inducing retrovirus gene insertion was the cause of the leukemia development 
in the children treated for X-SCID mentioned previously. Besides gene integration issues, native 
components of the viruses themselves might also cause cancer under certain conditions [47-
48]. 
1.5.3 Cell Targeting 
In addition to delivering the therapeutic gene into the correct location in the cell‟s genome, 
another key component in gene therapy design is to have the vector delivered to the right type 
of cells. Even though all of the patient‟s cells contain the defective, disease-causing gene, only 
specific cells and tissues actually express the gene and need to be treated with gene therapy. 
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For example, OTCD is caused by a genetic mutation expressed in the liver; it would be 
desirable to design gene delivery vectors that would target specifically liver cells expressing the 
mutation in order to increase the efficiency of the treatment [49]. Viruses have evolved to be 
efficient at targeting specific cells, and one can enhance the cell targeting ability of viruses by 
using either transductional targeting or transcriptional targeting. In transductional targeting, 
ligands are attached to the surface of the viruses, or viruses are engineered to express the 
surface ligands, to target the receptors of specific cells [49-50]. In transcriptional targeting, the 
genetic material inside the viruses is altered to contain a promoter that will be triggered for 
transgene expression only if the virus is inside a specific cell type [51-52]. Even with detailed 
virus engineering, the native tropism of the viruses is intact, and the risk of the viruses infecting 
cells surrounding the target tissues remains.  
1.5.4 Development and Production 
The production of retroviral vectors for gene therapy involves two components: the retrovirus 
and the retrovirus packaging cell line. The retrovirus carries all the essential viral genes except 
the gene for viral proteins, which is provided by the retrovirus packaging cell line. By infecting 
the packaging cell line with retrovirus, one can produce retroviral vectors with desired properties 
or titer [104-105]. This production process has two major drawbacks: 1) the size of the gene that 
can be inserted into the retroviruses is limited to about 10 kbp and may not be appropriate for 
the therapeutic gene of interest; and 2) the expression of pathogenic viral proteins from any 
intact viral genes could trigger the host‟s fatal immune response. Because of these potential 
downfalls, a safer alternative virus production pathway involving gutted adenoviruses is being 
explored. In this case, the viruses only consist of the gene for packaging and replication. Larger 
therapeutic genes can be inserted into gutted viruses, reducing the risk of viral proteins due to 
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the removal of excess viral genes from the process. However, this process is more complex and 
labor-intensive compared to regular retrovirus production [53-55]. 
Most current virus production is targeted for lab bench-scale experiments. Both the packaging 
cell lines and purifications involved are expensive and difficult to scale up for mass production of 
viruses [56-57]. Without a more efficient and cost-effective method to mass produce viruses, 
viral gene therapy will remain a highly individualized treatment if approved.  
1.6 Non-Viral Gene Delivery Vectors 
Given the inherent properties of viral vectors in efficiently infecting various cell types and 
transferring genetic materials into the cell‟s nucleus, viruses have been extensively studied in 
clinical trials for gene therapy. However, as discussed above, viruses present many problems 
for in vivo gene therapy, including oncogenicity, pathogenicity, and cost. As a result, 
researchers have been exploring alternative materials that would provide similar gene delivery 
properties as viruses yet do not trigger immune responses from the patient and are relatively 
inexpensive to synthesize. Two such materials that are being studied to replace viral vectors are 
cationic lipids and polymers. The cationic surface charge of these non-viral vectors allows 
complexation with negatively charged DNA to form a shield to protect DNA from degradation. 
Some common lipids and polymers used in gene delivery research are shown in Figure 1.1. 
Unlike viruses, synthetic vectors need to overcome many barriers, both intracellular and 
extracellular, for successful transfection. A basic schematic of the process of non-viral gene 
delivery is shown in Figure 1.2. Much research has been invested into increasing the efficiency 
of non-viral vectors by improving their ability to bind to the cell surface and to escape cellular 
degradation mechanisms. 
1.6.1 Advantages and Disadvantage of Non-viral Gene Delivery Vectors 
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One of the main advantages of using non-viral vectors over viral vectors in gene delivery is that 
non-viral vectors are generally non-immunogenic and non-pathogenic. More importantly, unlike 
viruses, synthetic vectors do not insert genes into the cell‟s genome, thus eliminating the risk of 
random insertion mutation. A summary of advantages and disadvantages of viral and non-viral 
vectors in gene delivery is listed in Table 1.1. Even though non-viral vectors show many good 
qualities as a gene delivery carrier, the main problem that plagues non-viral vectors from being 
a viable gene therapy option is its poor transfection efficiency compared to viruses. To 
understand this inefficiency in non-viral gene therapy, one needs to understand the cellular 
barriers and mechanisms involved in order for synthetic vehicles to deliver therapeutic gene into 
the cell‟s nucleus. 
1.6.2 Extracellular Barriers 
Unlike viruses, non-viral gene delivery vectors do not possess the natural ability of infecting 
cells and inserting genes into the host‟s nucleus. Polymer/DNA complexes (polyplexes) need to 
overcome many obstacles in order to reach and then enter the cells. For in vivo experiments, 
once the polyplexes are injected into the animal, they need to first withstand the degradative 
enzymes and serum proteins present in the blood stream. If cationic polymers do not condense 
the gene tightly or completely shield the gene from the enzyme, the gene will be digested, 
resulting in reduced delivery efficiency. Also, the serum protein in the bloodstream is negatively 
charged, which causes it to bind with the polyplexes that exhibit positive surface charge. If too 
much serum protein attaches to the polyplexes, the aggregates that form may be accumulated 
or filtered out by the liver or spleen [58]. One way to reduce serum protein aggregation is to 
shield the positive surface charge of the polyplexes from their surroundings by attaching 
biocompatible hydrophilic polymers like polyethylene glycol (PEG) [59-60].  
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Assuming the polyplexes have avoided the enzymatic degradation in the blood stream and 
reached the vicinity of the cells, they then need to attach themselves to the cells‟ surface in 
order to be internalized. The cationic surface charge of the polyplexes can naturally bind to the 
negatively charged cell surface through electrostatic interactions. However, this process is 
highly non-specific and leads to binding with surfaces of random cells instead of just the target 
cell type. Research has been done to attach various targeting ligands to the surface of the 
polyplexes to increase their targeting abilities. For example, transferrin and folate have been 
used as ligands to target the over-expressed receptors on cancer cells‟ surfaces to improve the 
efficiency of the non-viral gene delivery [61-62]. 
Due to their large size, the polyplexes cannot diffuse through cell membranes and must be 
internalized by a process calls endocytosis, where the cell membrane forms a vesicle around 
the polyplexes and pinches off into the cytosol. Endocytosis is generally classified into two 
groups: phagocytosis, for uptaking large particles, and pinocytosis, for uptaking smaller 
particles, fluid, and solutes. Phagocytosis happens in a limited number of cell types, where 
pinocytosis occurs in virtually all cells and is one of the most important pathways in gene 
delivery. There are four main types of pinocytosis: marcopinocytosis, clathrin-mediated 
endocytosis, caveolin-mediated endocytosis, and clathrin/caveolin-independent endocytosis 
(Fig 1.3). Each pathway will result in different sizes of vesicle and leads to different subsequent 
intracellular processes for the endocytosed polyplexes [63].  
1.6.3 Intracellular Barriers 
Once a non-viral gene delivery vector is internalized from the cell‟s surface via pinocytosis, it will 
initially be located within either a caveosome or an early endosome, for caveolin-mediated and 
clathrin-mediated pathways, respectively [64-65]. The clathrin-mediated pathway always leads 
to early endosomes, in which some will recognize the polyplex as a foreign object and 
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exocytose it. Otherwise, the early endosome will acidify and eventually become a lysosome and 
degrade the polyplex. For caveolin-mediated pathways, the caveosome remains at neutral pH 
and does not end up in lysosome. However, the fate of the caveosome is not well established. 
Evidence has suggested that caveosomes may merge into clathrin-mediated pathway in the 
early endosome stage or be localized into recycling endosomes [112-115]. Regardless of 
uptake pathway, the ability of escaping from the endsosome prior to lysosomal digestion is one 
of the most crucial factors that dictate the efficiency of a non-viral gene delivery system. For lipid 
gene delivery, it has been speculated that the cationic lipid mixes with the negatively charged 
lipids in the endosome, which causes a reduction in the lipid‟s DNA condensation strength and 
leads to the release of the DNA into the cytosol [66]. Unlike lipids, certain cationic polymers, like 
PEI, have a completely different proposed mechanism, called the proton sponge effect, for 
escaping endosomes. In general, ATPase on the endosomal membrane actively transports 
protons into the early endosome to acidify the endosomal environment. Due to the high density 
of secondary and tertiary amines on the polymer with pKa values between physiological and 
lysosomal pH, proton sponge materials like PEI prevent the acidification of the endosome by 
absorbing the protons through the protonation of their own amine groups. As a result, the 
ATPase transports more protons into the endosome to try to reach the target acidic pH. To 
retain electroneutrality, an increased amount of counter ions, mainly chloride, are also 
transported into the endosome, leading to an increase in internal osmotic pressure, endosomal 
swelling, and eventual burst (Fig 1.4). 
After the polyplex escapes from the endosome, it must travel through the cytosol to reach the 
nuclear membrane. Studies have shown that random diffusion is unlikely to be responsible for 
moving the polyplex to the nuclear membrane [67]. Based on fluorescent particle tracking 
experiments, microtubules and filaments appear to actively transport the polyplex through 
cytosol using molecular motors [68-69]. 
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One of the last intracellular trafficking barriers the polyplexes need to overcome after reaching 
the nuclear membrane is to gain entrance to the nucleus and unpack the gene inside the 
nucleus [70-72]. There are three possible methods the polyplexes use for nuclear entry. The 
first method involves the polyplexes utilizing the nuclear pores on the membrane for entrance. 
There are thousands of the tiny pores, ~150 nanometers in diameter, on the surface of the 
nuclear membrane that open or close depending on the presence of a nuclear localization 
signal (NLS) on the object trying to enter [106]. In their open state, the pores allow active 
transport of molecules with a diameter of ~26 nanometers, while in their closed state, the pores 
only allow molecules with diameters less than 9 nm to diffuse through [73]. As a result, research 
has been done to covalently attach NLS to DNA to induce the opening of the nuclear pores for 
active transport of DNA, and potentially entire polyplexes, into the nucleus [74-75]. The second 
nuclear entry method involves polyplexes entering the nucleus through the breakdown of the 
nuclear envelope during mitosis. As the cells split into two daughter cells, the nuclear envelope 
breaks open and allows the negatively charged chromatin to interact with the cationic 
polyplexes and to competitively displace DNA from the cationic polymers. The displaced DNA is 
then trapped inside the nucleus as the nuclear envelope is reconstructed after mitosis, allowing 
the DNA to be transcribed inside the host‟s nucleus. Studies have shown that gene delivery 
efficiency increases when cells are dividing [76]. With the understanding of the extracellular and 
intracellular barriers involved with non-viral gene delivery in mind, it is important to choose 
materials that condense and protect DNA, are able to be internalized by cells, escape the 
endosome, and carry the DNA to the nucleus. As mentioned earlier, two of the most heavily 
researched materials that fulfill all of these requirements are cationic lipids and polymers. 
1.6.4 Lipid-Mediated Gene Delivery 
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Cationic lipids, like 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 
dioleoylphophatidylethanolamine (DOPE), and N-[1-dioleyloxy)propyl]-N,N,N-
trimethylammonium (DOTMA), are commonly used to complex with DNA to form lipoplexes for 
lipid-based gene delivery [107]. Cationic lipids consist of three major components: a 
hydrophobic lipid anchor group, a linker group, and a positively charged headgroup. The 
hydrophobic lipid anchor helps the formation of liposomes, the headgroup condenses the DNA, 
and the linker group dictates the stability of the lipids. For example, the ether linker between 
headgroup and acyl chain of DOTMA is more stable than the labile ester linkage of DOTAP 
[108]. In additional to the property of the linker group, the valence of the lipid headgroup has 
also been shown to affect the lipid‟s gene transfer capability [109-110]. The overall transfection 
efficiency of lipoplexes is very low compared to viruses due to the intracellular barriers 
mentioned above. . Researchers have explored the addition of helper lipids and targeting 
ligands to lipoplexes to facilitate endosomal escape and to increase cell targeting and uptake. 
Both strategies have shown an improvement in transfection efficiency [77-79]. 
1.6.5 Polymeric Gene Delivery 
Cationic polymers, like poly-l-lysine (PLL), polyamidoamine (PAMAM) ,polyethylenimine (PEI), 
poly(-amino ester)s, and poly(2-(dimethylamino)ethyl methacrylate) (pDMAEMA), are heavily 
studied as potential gene delivery vehicles due to their capability to condense negatively 
charged DNA and protect the DNA from its cellular surroundings. Poly(-amino ester)s have 
been shown to mediate gene transfer better than Lipofectamine 2000, a commercial lipid-based 
gene delivery reagent [111], However, unlike poly(-amino ester)s, other cationic polymers are 
plagued by either low transfection efficiency (PLL, pDMAEMA) or high toxicity (PEI and 
PAMAM), making them non-ideal gene delivery vectors [80-82]. Similar to lipoplex gene 
delivery, many researchers have investigated different synthesis strategies to increase the 
16 
 
efficiency of these non-viral vectors via aiding the endosomal escape, lowering the toxicity, or 
improving cell targeting. For example, melittin, an endosomolytic peptide, is added onto PLL 
polyplexes to aid their endosomal escape capability [83]. Polyethylene glycol (PEG) has been 
added onto PAMAM to shield the positive surface charge from the cells, reducing toxicity and 
increasing efficiency [84].  
Compared to other cationic polymers, PEI is one of the most commonly used in gene delivery. 
In addition to its ability to condense DNA, it has also shown relatively high transfection efficiency 
in vitro. PEI is cheap and commercially available in linear or branched form in different 
molecular weights from 0.8 to 1000 kDa. It has high primary, secondary, and tertiary amine 
densities, which allows easy functionalization of PEI with ligands to enhance its cell targeting 
and uptake [85-87]. The 25-kDa unmodified form of PEI has been shown to have the highest 
transfection efficiency in vitro but its high toxicity prevents it from being used clinically. As a 
result, it is commonly used as a transfection reference standard to compare with other newly 
synthesized gene delivery vectors. Much research has been done to reduce the toxicity of PEI 
while improving its efficiency and cellular uptake by modifying or functionalizing the polymer‟s 
structure. One of the main strategies being used to achieve this goal is to cross-link low 
molecular weight PEI, which is relatively non-toxic, with a degradable cross-linker.  
1.7  Biodegradable Cross-linked Polyethylenimine 
In general, gene delivery efficiency is directly related to the molecular weight of PEI, while 
toxicity is inversely related. Gosselin et al. concluded that 25 kDa PEI displays gene delivery 
efficiency 50-fold higher than 800 Da PEI but reduces cell viability by more than half [88]. Since 
material toxicity should be one of the major considerations in any gene delivery vector‟s design, 
researchers have explored various alternatives to temporarily increase the molecular weight of 
low molecular weight cationic polymers. The resulting polymers would condense DNA and 
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possess gene delivery efficiency similar to their high molecular weight counterparts and degrade 
into a less toxic low molecular weight version of the polymers inside the cells. One common 
approach is to insert a degradable cross-link between low molecular weight cationic polymer 
molecules. Many syntheses have been investigated to cross-link polymers using different cross-
linker-polymer combinations. Petersen et al. have synthesized a biodegradable PEI derivative 
by linking PEI with oligo(L-lactic acid-co-succinic acid) (OLSA, 1000 Da) (Figure 1.5). The 
resulting polymer displays 10-fold increases in transfection efficiency and minimal toxicity 
compared to 25 kDa PEI [89]. Another version of degradable PEI is synthesized by linking 1.8 
kDa PEI and glutadialdehyde with acid-labile imine linker that shows 30% improvement in 
toxicity but displays only about 80-90% of 25 kDa PEI‟s transgene expression (Figure 1.5) [90]. 
These results indicate that the cross-linking design is crucial for synthesizing degradable 
synthetic gene delivery vectors that show both low toxicity and high efficiency. 
1.7.1 Disulfide Cross-linked Polymers 
One of the specific cross-linking strategies that have been commonly used in peptide, PLL, PEI, 
and other polycations is the formation of disulfide cross-links. Because disulfide bonds will 
cleave under reducing conditions, the high molecular weight cross-linked materials will revert 
back to their original low molecular weight form inside the cytoplasm, aiding the release of DNA 
and reducing overall toxicity. McKenzie et al. showed that a disulfide cross-linkage between 
peptides increases the buffering capacity of the peptide/DNA complexes and improved gene 
delivery efficiency (Figure 1.6) [91]. By combining PEG and PLL to form block cationic 
polyplexes through disulfide bonding, Miyata et al. improved the stability of the polyplexes and 
increased transfection efficiency by at least 100-fold compared to PLL alone (Figure 1.6) [92]. 
Peng et al. reported a disulfide cross-linked PEI prepared by thiolation of 800 Da PEI that shows 
comparable transfection efficiency and improved toxicity compared to 25 kDa PEI (Figure 1.6) 
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[93]. Unfortunately, not all polymers with disulfide linkages show an increase in transgene 
efficiency. Gosselin et al. have disulfide cross-linked 800 Da PEI with 
dithiobis(succinimidylpropionate) (DSP) and dimethyl·3,3„-dithiobispropionimidate·2HCl (DTBP). 
The resulting polyplexes only improve the toxicity but cannot outperform 25 kDa PEI in 
transgene expression (Figure 1.6) [88]. 
1.7.2 Diacrylate Cross-linked PEI 
Another strategy used in synthesizing degradable polycations is the Michael addition of amines 
to acrylate groups. Lynn et al. screened a library of 140 diacrylate cross-linked amine polymers, 
showing some specific combinations of diacrylates and amine monomers with promising 
transgene expression [94]. Since then, many researchers have studied further the gene delivery 
properties of those polymers reported by Lynn et al. Forrest et al. detailed the synthesis of 
degradable PEI derivative by cross-linking 800 Da PEI with 1,3-butanediol diacrylate and 1,6-
hexanediol diacrylate. The resulting polycations showed two- to 16-fold increase in transfection 
efficiency compared to 25 kDa PEI, and are essentially non-toxic [95]. Using a similar reaction 
scheme, Dong et al. synthesized cross-linked PEI with 800 Da PEI and 1,4-butanediol diacrylate 
and reported that the new polymer mediates comparable gene expression to 25 kDa PEI in vitro 
but not in vivo [96]. To further the study of Lynn et al., Thomas et al. used high-throughput 
synthesis and screening to test the in vitro and in vivo transfection efficiency of 24 bi- and oligo-
functional acrylates separately cross-linked with linear 423 Da PEI and branched 1.8 kDa PEI 
[97]. They concluded that tricyclo [5.2.1.0] decame-dimethanol diacrylate cross-linked PEI 
derivative shows 3,600-fold improvement in transfection over the non-cross-linked 423 Da PEI 
in vitro, and mixed PEIs (423 Da PEI plus 1.8 kDa PEI) cross-linked with propylene glycol 
glycerolate diacrylate mediates 53-fold higher gene expression than the non-cross-linked 
version in vivo. In addition to transfection and toxicity studies, research has also been done to 
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characterize the degradation of diacrylate cross-linked PEI derivatives using real time 1H NMR 
and Monte Carlos simulations [98]. 
1.7.3 PVP(Fe(III)) Catalyzed Biodegradable PEI Synthesis 
As discussed above, Forrest et al. first reported the synthesis of degradable PEI by cross-linking 
low molecular weight PEI with diacrylates. The resulting PEI derivatives show minimal toxicity 
and increased gene delivery efficiency compared to 25 kDa PEI [95]. However, the synthesis 
was reported to be difficult to control and inconsistent. In this project, we investigated a different 
synthesis of the degradable PEI derivatives reported by Forrest et al. by utilizing poly(4-
vinylpyridine) (PVP)-supported Fe(III) heterogenous catalyst. Fe(III) has the ability to catalyze 
the diacrylate cross-linking reaction, but separating it from PEI post-synthesis is difficult due to 
PEI‟s metal chelating potential [99]. By incorporating polymer support, the PVP(Fe(III)) 
heterogenous catalyst provides a low cost catalyst that catalyzes the synthesis of degradable 
PEI and allows easy catalyst recovery [100]. As a result, this alternative synthesis scheme 
provides a more controllable PEI cross-linking method and degradable PEIs with wider range of 
molecular weights. In the following chapters, we detail the synthesis and characterization of the 
degradable PEIs, involving catalysis by PVP(Fe(III)) for cross-linking of 800 Da PEI with 1,6-
hexanediol diacrylate. These degradable PEIs‟ molecular weights range from 1.2 kDa to 48 
kDa, and these materials also show higher transfection efficiency and cellular uptake, while 
showing minimal toxicity, compared to unmodified 25 kDa PEI in HeLa and MDA-MB-231 cell 
lines.  
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1.8 Tables and Figures 
 
Figure 1.1: Commonly used cationic polymers and lipid for non-viral gene delivery [116] 
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Figure 1.2: Cellular mechanisms involved in non-viral gene delivery. Complexes must 
overcome many barriers, including cell surface binding, endocytosis, exocytosis, lysosomes, 
endosomes, nuclear entry, and DNA unpackaging, in order to carry the therapeutic gene into 
the host‟s nucleus for transfection [101] 
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Table 1.1: Advantages and disadvantages of viral and non-viral vectors for gene therapy 
 
Viruses Non-Viral Vectors 
Immunogenicity High Low 
Pathogenicity High None 
Oncogenicity High None 
Toxicity Low High 
Efficiency High Poor 
Cell Targeting Ability Difficult to Adjust Easy to Modify 
Availability Low/Custom Made Readily Available 
Cost Expensive Cheap 
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Figure 1.3: A simplified schematic summarizing various endocytic pathways into cells [102] 
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Figure 1.4: Schematic of endosomal escape through proton sponge mechanism [101] 
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Figure 1.5: Reaction schematics of various cross-linked polymers. A) Petersen et al. 
synthesized biodegradable vector by cross-linking 1.2 kDa PEI with oligo(L-lactic acid-co-
succinic acid) (OLSA) [89] and B) Kim et al. used acid-labile imine linker (glutadialdehyde) to 
produce a biodegradable PEI gene carrier [90] 
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Figure 1.6: Reaction schematics of various disulfide cross-linked polymers: A) McKenzie et al. 
synthesized a stable peptide DNA condensate by binding poly-l-lysine peptides containing Cys 
residues with plasmid DNA through the formation of disulfide bond [91], B) Miyata et al. thiolated 
poly(ethylene glycol)-poly(L-lysine) block copolymer with N-succinimidyl 3-(2-
pyridyldithio)propionate (SPDP) or 2-iminothiolane to form a cationic polymer with disulfide 
cross-linked backbone [92], C) Peng et al. prepared a disulfide cross-linked PEI through the 
oxidation of a thiolated PEIs with DMSO D) Gosselin et al. disulfide cross-linked PEI with 
dithiobis(succinimidylpropionate) (DSP) and dimethyl•3,3-dithiobispropionimidate•2HCl [88],   
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Chapter 2 
 
Materials and Methods 
2.1 Cells and Plasmids 
The MDA-MB-231 human breast carcinoma cell line was purchased from the American Type 
Culture Collection (Manassas, VA). The HeLa human cervical carcinoma cell line was a gift from 
Dr. Sandra McMasters (University of Illinois, Urbana, IL). Cells were cultured according to their 
ATCC protocols at 37 oC and 5% CO2 in Dulbecco‟s modified Eagle‟s medium (DMEM). The 
growth medium was supplemented with 10% fetal bovine serum (FBS) and 10% penicillin-
streptomycin. The 5.3-kilobase expression vector pGL3 (Promega, Madison, WI), coding for 
firefly luciferase gene driven by the SV40 promoter and enhancer, was purchased from Elim 
Biopharm (Hayward, CA) and used without further purification. 
2.2 PVP(Fe(III)) Catalyst and Degradable Polyethylenimine Syntheses  
Polymer supported ferric chloride was synthesized by suspending 1 g of poly(4-vinylpyridine) 
(PVP) in 10 mL of 0.1 M FeCl3 solution in double-filtered water in a 20-mL scintillation vial, 
resulting in a clear yellow solution with white powder in suspension. An additional 161 mg (1 
mmol) of FeCl3 was added, and the mixture turned into a cloudy reddish brown color. The 
mixture was stirred with a stir bar at room temperature for 30 minutes, during which the overall 
mixture color remained the same, and the solid suspension color changed from white to reddish 
orange. The PVP-immobilized Fe(III) solid was filtered with filter paper under vacuum, washed 
with double-filtered water, and dried at 60oC overnight. The resulting catalyst was a reddish 
orange powder that was used without further purification. 
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Degradable PEI was synthesized by cross-linking 800 Da branched PEI with 1,6-hexanediol 
diacrylate cross-linker. Briefly, 1 g of 800 Da branched PEI was dissolved in 10 mL of methanol 
at room temperature in a scintillation vial. Various molar equivalents of PVP(Fe(III)) catalyst to 
mole of PEI, between 0.05 to 0.15, in addition to an equimolar amount of cross-linker to PEI, 
were added into the mixture to form a suspension. The mixture was sealed with a screw cap 
and wrapped in Parafilm and stirred with a stir bar overnight at 60oC. After 24 h, the mixture was 
transferred into a 15 mL polystyrene tube and centrifuged at 4500 rpm for 10 min to remove the 
catalyst. Unreacted materials were extracted using approximately 15 mL of petroleum ether. 
The methanol phase was collected, and methanol was removed by using a rotating evaporator 
at 67 oC and 150 rpm for approximately 25 min until only viscous degradable PEI sample was 
left. Polymer was used without further purification and stored at -80oC.  
2.3 Determination of Molecular Weight 
Based on the method previously described by von Harpe et al., capillary viscometery was used 
to determine the molecular weight of the degradable polymer samples. Briefly, polymers were 
dissolved in 0.5 M NaNO3 to achieve three different solutions with concentrations between 1 to 
5 g/L, and the viscosities were measured using a kinematic viscometer (Cannon, State College, 
PA) at 25 oC. Due to the high cationic charge of the polymer, the high salt concentration of 
NaNO3 is needed in order to obtain a linear relationship between polymer concentration and 
viscosity. Reduced, specific, inherent, and limiting viscosities of the polymer solution were 
calculated using Equations 1, 2, and 3: 
000 //)( ttsp    ................................................. (1) 
cspred /   ................................................................... (2) 
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where   is the viscosity of the polymer sample in solvent, 0  is the viscosity of the solvent 
(determined experimentally), 
sp  is the specific viscosity of the polymer sample in solvent, t  is 
the time the polymer sample in solvent took to go through the viscometer, 0t  is the time the 
solvent took to go through the viscometer, red  is the reduced viscosity of the polymer sample in 
solvent, c  is the concentration of polymer in the solvent, and ][ is the intrinsic viscosity of the 
polymer sample in solvent. 
Plotting ])log([ against )log(MW , a linear relationship was constructed using Staudinger-
Mark-Houwink relationship with known molecular weight PEI standards (Eqn 4):  
2)log()26.0(])log([  MW  ....................................... (4) 
By measuring the viscosity of each cross-linked polymer sample, one can calculate the 
molecular weight of the sample by using Eqn 1-4. 
2.4 1H NMR for Cross-linking Density Determination 
To determine the degree of polymer cross-linkage, 10 mg of each polymer was dissolved in D2O 
and 1H-NMR spectrum was acquired using Varian Unity 400 with a 5-mm probe. The extent of 
cross-linkage was determined by peak integration at: =1.25-1.40 ppm (br m, -
COOCH2CH2CH2, 2 H, ester linker), =1.40-1.60 ppm (br m, -COOCH2CH2, 2 H, ester linker), 
=2.33-2.47 ppm (br m, CH2CH2NHCH2CH2COOCH2, 2 H, ester linker), =2.47-3.3 ppm (br m, 
CH2CH2N, PEI ethylenes), =3.5-3.6 ppm (t, 
3J=6.6MHz, -HOCH2, 2 H, hydrolyzed ester linker), 
and =4.1 ppm (m, -COOCH2, 2H, ester linker). For the cross-linked PEI degradation study, 
each sample was dissolved in D2O and incubated at 37 
oC for 0 h, 24 h, 72 h, and 192 h, and 
the 1H spectrum was acquired using the same apparatus. The fraction of remaining cross-linked 
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PEI was determined by integrating and comparing the ester peaks at =4.1 ppm (m, -COOCH2, 
2H, ester linker) and =3.5-3.6 ppm (t, 3J=6.6MHz, -HOCH2, 2 H, hydrolyzed ester linker). 
The cross-link density of the cross-linked PEI was calculated based on the results from 
elemental analysis of the sample using mass balances, carbon and nitrogen balances in 
particular (Eqn 5-6): 
 )(*)(*)12()(*)(*)12( ybxa  ............................... (5) 
 )(*)(*)14()(*)(*)14( ydxc  ............................... (6) 
where a  is the number of carbon atoms in the PEI monomer, b  is the number of carbon atoms 
in 1,6-hexanediol diacrylate, c  is the number of nitrogen atoms in PEI monomer, d  is the 
number of nitrogen atoms in 1,6-hexanediol diacrylate, x  is the number of mole of cross-linked 
PEI monomer, y  is the number of mole of cross-linked 1,6-hexanediol diacrylate,   is the 
weight fraction of carbon in the cross-linked PEI sample, and   is the weight fraction of the 
nitrogen in the cross-linked PEI sample. With the values of a , b , c , and d  determined from 
the final product structure, x  and y  can be calculated. The cross-linking density was 
calculated based on the ratio of x  and y , and the assumption that there are an average of 20 
PEI monomer units per PEI chain. 
2.5 Characterization of Polyplexes 
2.5.1 Gel Retardation Studies 
One microgram of DNA was diluted into 10 µL of 120 mM NaCl, 16 mM PIPES at pH 7.2. 
Various amounts of polymer were dissolved in double distilled water and added to the 10 µL 
DNA/PIPES solution to form the desired polymer and DNA weight–to-weight ratio polyplexes. 
The polyplexes were incubated at room temperature for 15 min before adding DNA sample 
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buffer (Biorad). The samples were electrophoresed on a 1% agarose gel for 30 min at 120 V. 
The gel was visualized with ethidium bromide staining. 
2.5.2 Ethidium Bromide Exclusion Assay 
One microgram of DNA was diluted into 250 µL of 120 mM NaCl, 16 mM PIPES at pH 7.2. 
Various amounts of polymer were dissolved in double distilled water and added to the 250 µL 
DNA/PIPES solution to form the desired polymer and DNA weight–to-weight ratio polyplexes. 
The polyplexes were incubated at room temperature for 15 min in a 96-well microplate before 
adding 0.5 g of 1 g/L ethidium bromide into each polyplex sample to reach a final ethidium 
bromide concentration of 5 M and incubating at room temperature for another 10 min. 
Fluorescence was excited at 510 nm and emission detected at 595 nm (Bio Tek, Winooski, VT). 
The sample fluorescence value was normalized by values for wells containing DNA only, after 
subtracting background fluorescence measured from wells containing ethidium bromide only. 
Each measurement was performed in triplicate.  
2.5.3 Heparan Sulfate Displacement 
Polyplexes with 1 µg DNA were formed based on the optimal polymer/DNA ratio for transfection 
for each polymer in 15 µL of 120 nM NaCl, 16 mM PIPES at pH 7.2. Polyplexes were incubated 
at room temperature for 15 min before various amounts of heparan sulfate, dissolved in double-
distilled water, were added into each sample to achieve various weight-to-weight ratio between 
heparan sulfate and DNA. The mixture was incubated at room temperature for another 15 min 
after which 3 µL of DNA sample buffer was added into each mixture. The final mixture was 
loaded onto a 1% agarose gel and electrophoresed for 30 min at 120 V. The gel was visualized 
with ethidium bromide. For the PEI degradation study, each polymer was incubated at 37 oC for 
0 h, 24 h, 72 h, and 192 h. Polyplexes and heparan sulfate displacement assay were prepared 
as mentioned above. 
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2.5.4 Dynamic Light Scattering 
One microgram of DNA was diluted into 200 µL of 120 mM NaCl, 16 mM PIPES at pH 7.2. 
Polymer was dissolved in double distilled water. The amount of sample used was determined by 
the optimal transfection ratio and diluted into 200 µL of 120 mM NaCl, 16 mM PIPES at pH 7.2, 
and was added to the 200 µL DNA/PIPES solution to form the desired polymer and DNA 
weight–to-weight ratio polyplexes. The polyplexes were incubated at room temperature for 15 
min and double distilled water was added to reach a final sample volume of 2 mL. The 
polyplexes‟ size was measured by Brookhaven Instruments Corporation 90 Plus Particle Size 
Analyzer (Holtsville, NY) before and after 4 h of incubation at 37 oC. Each measurement was 
repeated five times.  
2.6 In Vitro Transfection 
Cells (MDA-MB-231 or HeLa) were cultured in DMEM with 10% fetal bovine serum and 10% 
penicillin-streptomycin. In a 24-well plate, 8x104 cells/well were seeded in growth medium with 
serum 24 h before transfection. On the day of the transfection, growth medium was replaced 
with fresh serum-free DMEM. Before transfection, 50 µL polyplexes in 120 nM NaCl, 16 mM 
PIPES at pH 7.2 were formed with 0.5 g pGL3 and various amount of polymer to achieve 
desired weight-to-weight ratio. The polyplexes were incubated at room temperature for 15 min 
and added into each well (50 µL polyplexes/well). Four hours post-transfection, DMEM was 
replaced with fresh growth medium with serum, and incubated for another 20 h. Twenty-four 
hours post-transfection, luciferase expression was determined using the Promega Luciferase 
Assay System (Promega), which reports expression levels as relative light units (RLU) as 
measured on the Lumat L 9507 luminometer (Berthold, GmbH, Germany). Each experiment 
was performed in quadruplicate. Luciferase expression results (RLUs) were normalized to total 
cell protein amount using BCA Protein Assay Kit (Thermo Scientific, Rockford, IL) 
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2.7 Cytotoxicity  
The cytotoxicity of polymer on the MDA-MB-231 and HeLa cells were characterized using the 
CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT) (Promega) according to 
manufacturer‟s protocol. Briefly, 8x103 cells/well were seeded in 96-well microplate in growth 
medium containing 10% FBS and incubated at 37 oC and 5% CO2 overnight. Approximately 24 
h after seeding, the medium was replaced with serum-free DMEM, and various amount of 
polymer was added to the cells to achieve a final concentration between 0 and 50 µg/mL. 
Following a 4 h incubation period at 37 oC and 5% CO2, the medium was replaced with fresh 
serum-containing medium and incubated for another 24 h, after which 15 µL of the Dye Solution 
was added into each well, and cells were incubated for another 4 h. After incubation, 100 µL of 
the Solubilization Solution/Stop Mix was added into each well and incubated for another 1 h. 
Afterward, the absorbance at 570 nm, with reference wavelength of 650 nm, was measured 
using Tecan Safire 2 Fluorescence Reader (Tecan, Mannedorf, Switzerland). The absorbance 
of medium only was subtracted from the viable cell absorbance and normalized to cells with no 
polymer. Each polymer and polymer concentration were tested six times in each experiment.  
2.8 Polyplex Internalization 
Cells (MDA-MB-231 or HeLa) were cultured in DMEM with 10% fetal bovine serum (FBS) and 
10% penicillin-streptomycin. In a 24-well plate, 8x104 cells/well were seeded in growth medium 
with serum 24 h before transfection. On the day of the transfection, growth medium was 
replaced with fresh serum-free DMEM. The intercalating dye YOYO-1 was mixed with pGL3 
according to the ratio 25 nL YOYO-1 for every 1 µg DNA (67 bp/YOYO-1). Fifty microliters of 
polyplexes in 120 nM NaCl, 16 mM PIPES at pH 7.2 were formed with 0.5 µg pGL3/YOYO-1 
and various amount of polymer to achieve desired weight-to-weight ratio. Two hours post-
transfection, the cells were washed with 0.001% SDS in PBS to remove surface-bound 
complexes. One hundred microliters of non-phenol trypsin was added into each well and 
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incubated for 10 min before adding 350 µL PBS and 50 µL FBS. The cells were collected and 
stored on ice before measurement. FACS measurements were performed on a BD LSR II Flow 
Cytometer System (BD, Franklin Lakes, NJ). To determine uptake, median peak fluorescence of 
polyplexes was recorded and normalized with pGL3/YOYO-1 only samples‟ median peak 
fluorescence. Each measurement was performed in triplicate. 
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Chapter 3 
Results 
3.1 Biodegradable Polyethylenimine Characterization 
3.1.1 Synthesis and Characterization of Biodegradable PEI 
Based on the synthesis described in Materials and Methods, three biodegradable PEI samples 
were synthesized by cross-linking equal moles of 800 Da PEI with 1,6-hexanediol diacrylate, 
and catalyzed with 0.1, 0.15, and 0.2 molar equivalent of PVP(Fe(III)) catalyst per mole of PEI 
(Figure 3.1). The molecular weights of the biodegradable PEI (D.PEI) samples were 48 kDa, 
6.2 kDa, and 1.2 kDa, determined using capillary viscometry (Table 3.1) [1]. Compared to the 
degradable PEIs generated by the non-catalyzed reaction reported by Forrest et al., 14 kDa and 
30 kDa D.PEIs [2], this alternative synthesis scheme provides a wider range of D.PEI molecular 
weights for characterization and gene delivery studies. 
The structure and degradation of polymeric gene delivery vectors are important to their impact 
on safe, efficient gene transfer. Non-degradable PEI may accumulate inside the cell, increasing 
toxicity, and leading to reduced transfection efficiency. To investigate the structure and 
degradation of D.PEI samples, we incubated samples at 37 oC in D2O for various amounts of 
time and obtained their 1H NMR spectra. The 1H spectra confirmed the synthesis of ester 
linkages between PEI and 1,6-hexanediol diacrylate (Figure 3.2). To calculate the extent of 
D.PEI degradation, the relative number of methylene protons in the ester bond and in the 
hydroxyl group was determined by integrating the corresponding peaks in the spectra (Figure 
3.3 and 3.4) [6]. The degradation of D.PEIs was the most rapid in the first 24 h and eventually 
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slowed. Both 48 kDa and 1.2 kDa D.PEIs had about 50% of their initial ester bonds remaining 
after 24 h of incubation, while 6.2 kDa D.PEI reached its half-life after 72 h incubation.  
Another D.PEI characteristic of interest is the degree of cross-linking. Highly cross-linked, low 
molecular weight PEI is expected to behave similarly to its high molecular weight non-cross-
linked counterpart, including improved DNA binding and transfection efficiency, due to similar 
molecular weights. By utilizing elemental analysis, we approximated the cross-linking density of 
each D.PEI sample through mass balances (Table 3.2). As expected, the higher molecular 
weight D.PEI possessed higher degree of cross-linking, and vice versa: 48 kDa, 6.2 kDa, and 
1.2 kDa D.PEIs have cross-linking density, defined as mole percent of nitrogen atoms in PEI 
attached to 1,6-hexanediol diacrylate, of 16.9%, 15.1%, and 14.1%, respectively. In addition to 
cross-linking density, it is also important to understand the cross-linking structure of the D.PEIs. 
To determine whether the samples have linear or branched structure, we need to calculate the 
number of PEI chains cross-linked with 1,6-hexanediol diacrylate (Table 3.2) [3,7]. The results 
show that D.PEI samples with higher cross-link density have more diacrylates attached to a PEI 
chain compared to the lower cross-linked counterpart. More importantly, all three D.PEIs show 
that, on average, each sample has more than two diacrylates linked with a single PEI chain. 
This finding implies that the D.PEI samples possibly consist of branched structure. In particular, 
the 48 kDa D.PEI has more than three diacrylates attached to a PEI chain, which indicates a 
high level of branching. Due to the loss of flexibility and steric hindrances as a result of this 
branching, the D.PEIs tend not to condense DNA as efficiently as their unmodified 25 kDa 
counterpart, a trend which will be discussed below in greater detail. 
3.1.2 DNA Migration Inhibition 
One of the important characteristics of a good non-viral gene delivery vehicle is its ability to 
condense DNA efficiently, in order to be taken up by the cells. To measure the capability of the 
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polymer to condense DNA, one can electrophorese polyplexes formed at various polymer:DNA 
weight-to-weight ratio in agarose gel to observe the necessary amount of polymer needed to 
completely inhibit the DNA‟s migration (Figure 3.5). Unmodified 25 kDa PEI needed 0.2 g 
polymer/g DNA to completely retard the DNA. The D.PEI samples were able to retard DNA 
migration at 0.5 g polymer/g DNA ratio. Upon closer examination, one can see 48 kDa D.PEI 
prevented migration of most of the DNA with 0.3 g of polymer, while 0.4 g of polymer was 
needed for 6.2 kDa D.PEI and 1.2 kDa D.PEI. These results indicate unmodified 25 kDa PEI 
condensed DNA much more efficiently than the three D.PEI samples, even though we expected 
that cross-linking 800 Da PEI would result in polymer that behaved more like its higher 
molecular weight counterpart. This phenomenon can be attributed to a steric effect where some 
of the primary and secondary amines are covalently bonded with the cross-linker, and as a 
result, the amine groups are either shielded from the DNA or lost their flexibility to bind to the 
DNA, compared to the amines in unmodified PEI. 
3.1.3 Polyplex Sizing via Dynamic Light Scattering 
As mentioned earlier, the size of the polyplex directly affects its ability to be endocytosed by the 
cells. It is critical that the cationic polymer is able to condense DNA and form nanoscale 
complexes. To determine the size of the D.PEI complexes, dynamic light scattering technique 
was used to measure the polyplexes‟ effective diameters immediately after polyplex formation at 
each polymers‟ optimal transfection ratio, and again after 4 hours of incubation at 37 oC. One 
would expect the polyplex size to increase after incubation due to polyplex aggregation. . It is 
indeed the case, as shown in Table 3.3. Unmodified 25 kDa PEI polyplexes have the smallest 
effective diameter both before and after incubation, despite these polyplexes consisting of 7.5-
fold to12.5-fold less polymer than the three D.PEI polyplexes. This result shows that unmodified 
25 kDa PEI has higher DNA condensation strength than the D.PEIs, which indicates the 
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presence of higher cationic surface charges. For the D.PEIs, the polyplexes‟ diameters are 
inversely related to the molecular weights of the polymers before incubation. 1.2 kDa D.PEI 
polyplexes have the largest effective diameter, even though there was ~1.6-fold more polymer 
present, confirming that higher molecular weight PEI can condense DNA better than its lower 
molecular weight counterpart. The trend is not as clear after 4 h of incubation but one can still 
see the inverse relationship between molecular weight and polyplex size among the D.PEI 
samples. 
3.1.4 DNA Condensation Strength of PEI 
Besides the ability of condensing DNA, a good polymeric gene delivery vector must exhibit tight 
binding to the DNA to avoid early DNA release, which would reduce the efficiency of gene 
delivery. One way to measure the tightness of DNA binding is to measure the polymer‟s ability 
to exclude ethidium bromide, an intercalating dye that would attach to DNA and fluoresce, as an 
indicator of the “tightness” of the DNA condensation. To quantify the degree of condensation 
between D.PEIs and DNA, ethidium bromide fluorescence was measured by mixing ethidium 
bromide with various polymer and DNA ratio polyplexes (Figure 3.6). Unmodified 25 kDa PEI 
condensed DNA tightly at polymer:DNA weight-to-weight ratio 0.5:1 showing only 1% 
normalized fluorescence. The D.PEI samples required more polymers, 0.5 g, 1 g, and 1 g of 
polymer:DNA ratio for 48 kDa, 6.2 kDa, and 1.2 kDa D.PEI, respectively, to achieve minimum 
normalized fluorescence and similar DNA binding “tightness” as unmodified 25 kDa PEI. This 
indicates that although all PEI samples are able to tightly condense DNA with only a small 
amount of polymers, D.PEIs seem to form “looser” polyplexes than unmodified PEI. The 
normalized fluorescence of all PEI samples gradually increased and reached a plateau as 
polymer:DNA ratio increases. This is unexpected and is likely an artifact contributed by the 
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prolonged incubation time during sample preparation between polyplexes and ethidium 
bromide. 
3.1.5 DNA Competitive Displacement  
Upon entering the cells, the DNA inside the polyplexes must be released from the polyplexes in 
order for transcription to occur. One way to measure the polymer‟s DNA condensation, in 
respect to DNA release, is to displace the DNA with anionic proteoglycan like heparan sulfate. 
Heparan sulfate (HS) competitively displaces DNA from cationic vectors, and the amount of HS 
needed to completely replace DNA from polyplexes indicates the strength of the polymer‟s DNA 
binding [4-5]. To determine the relative DNA binding strength of the D.PEIs before and after 
degradation (0 to 192 hours incubation at 37 oC), along with unmodified 25 kDa and 800 Da 
PEIs, various amount of HS was mixed into polyplexes prepared at 2:1 polymer/DNA weight-to-
weight ratio and electrophoresed in agarose gel (Figure 3.7). For unmodified PEIs, 25 kDa PEI 
and 800 Da PEI needed about 18 g HS/g DNA and 12 g HS/g DNA to displace the DNA, 
respectively, as expected. All the D.PEI samples needed less HS compared to unmodified 25 
kDa PEI, about 12 g HS/g DNA, to dissociate the DNA. This indicates it is easier to 
unpackage DNA from the D.PEIs than the unmodified PEI, which might explain the more 
efficient gene transfer of D.PEIs. Approximately the same amount of HS is needed for all D.PEI 
samples and for the 800 Da PEI, indicating that molecular weight of the D.PEI is not the only 
factor that controls DNA binding. This explains why even the 48 kDa D.PEI sample needs less 
HS to displace DNA compared to the 25 kDa control. 25 kDa PEI represents a long, continuous 
network of cationic PEI, whereas D.PEI is a lowly cross-linked network of shorter (800 Da) PEI 
pieces with cross-linker covalently attached to its primary and secondary amines in between. As 
result, due to the steric effect and loss of flexibility discussed previously, DNA will attach more 
strongly to the higher overall positive charge of 25 kDa PEI than even the highest molecular 
49 
 
weight of cross-linked D.PEI. In the tested incubation period, there is no significant change in 
the amount of HS needed to release DNA from the polyplexes for all D.PEI samples. This is 
expected since D.PEIs and 800 Da PEI released DNA with the same amount of HS present, as 
a result, D.PEI degradation should not affect the competitive release of DNA. This could be due 
to the relatively low cross-linking density of the D.PEIs, where the DNA binding of the 
unmodified 800 Da PEI, the starting material of the D.PEI, might overwhelm the effect of the 
reduced DNA binding strength from cross-link degradation. 
3.2 Biodegradable Polyethylenimine Gene Delivery 
3.2.1 In Vitro Transfection 
Transfection efficiency of unmodified and cross-linked PEIs were studied in HeLa and MDA-MB-
231 cell lines (Figure 3.8 and Figure 3.9). In HeLa cells, at their respective optimal 
polymer:DNA weight-to-weight ratio, both 48 kDa and 6.2 kDa D.PEIs transfected about 5–fold 
more efficiently than unmodified 25 kDa PEI. Though not as efficient as the other two D.PEIs, 
the transfection efficiency of 1.2 kDa D.PEI is about 3-fold higher than that of unmodified PEI. In 
MDA-MB-231 cells, D.PEIs also mediated greater transgene expression than 25 kDa PEI, but 
not as significantly as with HeLa cells. At their optimal polymer:DNA ratio, 48 kDa and 6.2 kDa 
D.PEIs‟s transfection efficiency was about 1.6–fold higher than unmodified PEI, while 1.2 kDa 
D.PEI shows similar transfection efficiency as unmodified PEI. The optimal transfection 
polymer:DNA ratio was 2:1 for unmodified 25 kDa PEI in both HeLa and MDA-MB-231 cells. 
However, the D.PEIs‟ optimal transfection polymer:DNA ratios were different between the two 
cell lines. In HeLa cells, the optimal polymer:DNA ratios were 10:1, 10:1, and 25:1 for 48 kDa, 
6.2 kDa, and 1.2 kDa D.PEIs, respectively. In MDA-MB-231 cells, the optimal ratio for 48 kDa 
and 6.2 kDa D.PEIs was 15:1, while 1.2 kDa D.PEI‟s optimal ratio was 20:1. For all the D.PEI 
samples, the increased amount of polymers needed to achieve the optimal polymer:DNA ratio is 
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likely due to the weaker DNA condensation and “looser” DNA binding compared to unmodified 
PEI. As a result, to compensate, more polymers are needed to improve transfection efficiency. 
3.2.2 Cytotoxicity 
For any therapeutic treatment, safety is of the utmost importance. Therefore, it is important to 
choose materials that show minimal toxicity as a gene delivery vehicle. Studies have shown that 
higher molecular weight PEI is significantly more cytotoxic than its lower molecular weight 
counterparts [2-3]. In order for the D.PEIs to be considered as potential vectors for gene 
delivery, they need to demonstrate lower cytotoxicity than unmodified 25 kDa PEI. To measure 
the polymers‟ cytotoxicity, the MTT assay was used to measure viability of HeLa and MDA-MB-
231 cells when they were exposed to various amounts of polymers (Figure 3.10 and Figure 
3.11). Unmodified 25 kDa PEI displayed highest cytotoxicity and reduced cell viability to 10% at 
polymer concentrations of 15 g polymer/mL and 30 g polymer/mL in HeLa and MDA-MB-231 
cells, respectively. All D.PEIs show significantly lower cytotoxicity in both cell lines compared to 
unmodified PEI. 48 kDa D.PEI is the most toxic of the three D.PEI samples; at 50 g 
polymer/mL, it yielded 40% and 80% cell viability in HeLa and MDA-MB-231 cells. 1.2 kDa 
D.PEI is the least toxic D.PEI sample and showed minimal cytotoxicity in both HeLa and MDA-
MB-231 cells, 110% and 95% cell viability at 50 g polymer/mL, respectively. At the same 
concentration, 6.2 kDa D.PEI displayed 50% and 100% viability in the two cell lines. Regardless 
of polymer samples, MDA-MB-231 cells consistently show lower cell viability than HeLa cells, 
indicating that PEI is generally more toxic to MDA-MB-231 cells than to HeLa cells.  
3.2.3 Cellular Uptake 
Cationic polyplexes need to go through many cellular processes in order for transfection to 
succeed, the first of which is endocytosis. As discussed earlier, endocytosis is the process cells 
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use to uptake the polyplexes into the cytosol. It is generally a non-specific process unless there 
are targeting ligands attached to the polyplexes. By using fluorescence-activated cell sorting 
(FACS), we can measure the uptake of the fluorescently labeled polyplexes through non-
specific endocytosis and determine any existing relationship between transfection and cellular 
uptake of the polyplexes (Figure 3.12 and Figure 3.13). Overall, MDA-MB-231 cells 
endocytosed 2- to 3-fold more polyplexes than HeLa cells for all polyplexes at the tested 
polymer:DNA weight-to-weight ratios. For unmodified 25 kDa PEI, approximately the same 
amount was endocytosed across various polymer:DNA ratios in both HeLa and MDA-MB-231 
cells. HeLa cells displayed similar uptake of D.PEI and unmodified PEI polyplexes, except at the 
highest tested polymer:DNA ratio, 25:1, where the cells endocytosed slightly more 48 kDa 
D.PEI polyplexes than unmodified PEI polyplexes. Unlike HeLa cells, MDA-MB-231 cells 
endocytosed more D.PEI polyplexes than unmodified PEI polyplexes in the tested polymer:DNA 
ratios, except at the lower polymer: DNA ratios (2:1 and 5:1). At their respective optimal uptake 
polymer:DNA ratios, 48 kDa, 6.2 kDa, and 1.2 kDa D.PEI polyplexes show 3-, 7-, and 4-fold 
higher cellular uptake than unmodified PEI polyplexes.  
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3.3 Tables and Figures 
 
Figure 3.1: Synthesis of biodegradable PEI derivatives. 800 Da PEI is cross-linked with 1,6-
hexanediol diacrylate in methanol overnight at 60oC, catalyzed by PVP(Fe(III)) heterogenous 
catalyst. The diacrylate groups can react with primary and secondary amines of the PEI. 
 
  
O
O
O
O
NH2
n
 
PEI
NH
PEI
O
O
O
O
NH
n
 N
PEI
PEI
+
Methanol at 60oC 
catalyzed by 
PVP(Fe(III)) 
PEI w/ primary amine 
PEI w/ secondary amine 
53 
 
Table 3.1: Polymer concentrations, viscosity measurements, reduced viscosities, and molecular 
weights of biodegradable PEIs 
Molar Ratio 
of Catalyst 
to PEI 
Concentration 
(mg/mL) 
Average 
Time (s) 
SD Reduced 
Viscosity 
(dL/g) 
Molecular 
Weight (kDa) 
 2 240.79 0.33   
0.2  4 247.44 0.44 0.0968 6.2 
 6 250.00 0.49   
 2 232.83 13.59   
0.15  4 243.71 0.17 0.0636 1.2 
 7 250.75 0.34   
 2 243.58 0.45   
0.1  4 246.63 0.21 0.1651 48 
 7 251.59 0.12   
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Figure 3.2: NMR spectra of unmodified PEIs and D.PEIs. 1) Unmodified 800 Da PEI, 2) 
unmodified 25 kDa PEI, 3) 48 kDa D.PEI, 4) 6.2 kDa D.PEI, and 5) 1.2 kDa D.PEI. D.PEI 
spectrum peak labels: (a) =4.1 ppm, -COOCH2, ester linker; (b) =3.5-3.6 ppm, -HOCH2, 
hydrolyzed ester linker; (c) =3.34ppm, methanol residual; (d) =2.47-3.3 ppm, CH2CH2N, PEI 
ethylenes; (e) =2.33-2.47 ppm, CH2CH2NHCH2CH2COOCH2, ester linker; (f)=1.40-1.60 ppm, 
-COOCH2CH2, ester linker; and (g) =1.25-1.40 ppm, -COOCH2CH2CH2, ester linker.  
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Figure 3.3: NMR spectra of 48 kDa D.PEI showing the change in peak intensity for unhydrolzed 
ester linker (=4.1 ppm) in D2O at 37
oC for various incbuation periods: 1) 0 hour, 2) 24 hours, 3) 
72 hours, and 4) 192 hours. 
56 
 
Figure 3.4: Degradation of D.PEIs in D2O at 37
oC for various incbuation periods. Samples were 
measured with 400 MHz 1H NMR. Degradation was calculated based on the integrals of the 
ester linker and hydrolyzed ester linker peaks as described in Chapter 2. 
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Table 3.2: Elemental analysis results, calculated % cross-linking and # diacrylate cross-linked 
with a PEI chain for each D.PEI sample 
D.PEI 
Samples 
Weight % 
Carbon 
Weight % 
Nitrogen 
Weight  % 
Hydrogen 
% Cross-
linking 
# Cross-linker 
attached to a 
PEI chain 
48 kDa  46.85 19.96 10.46 16.9 3.14 
6.2 kDa  49.07 20.26 10.19 15.1 2.81 
1.2 kDa 50.65 20.46 10.50 14.1 2.62 
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Figure 3.5: Gel retardation study of polymer/DNA polyplexes. A) Unmodified 25 kDa PEI, B) 48 
kDa D.PEI, C) 6.2 kDa D.PEI, D) 1.2 kDa D.PEI. The polymer to DNA weight-to-weight ratio for 
each polyplex formation is listed above the corresponding lane   
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Table 3.3: The effective diameters of unmodified 25 kDa PEI and three D.PEIs‟ polyplexes 
before and after 4 hours incubation at 37oC, at their respective optimal transfection ratio 
Polymer Polymer:DNA 
(w/w) 
Effective 
Diameter (nm) 
(0 hour 
incubation) 
SD Effective 
Diameter (nm) 
(4 Hours 
Incubation) 
SD 
25 kDa Unmodified PEI 2 : 1 293.2 4.1 457.3 16.8 
48 kDa D.PEI 15 : 1 321.8 7.8 483.5 8.4 
6.2 kDa D.PEI 15 : 1 405.2 5.2 481.5 19.0 
1.2 kDa D.PEI 25 : 1 440.4 3.4 551.5 12.0 
60 
 
 
Figure 3.6: Ethidium bromide exclusion assay. Polyplexes were formed with unmodified 25 kDa 
PEI and D.PEIs with DNA at various weight-to-weight ratios in the presence of ethidium 
bromide. Normalized fluorescence was calculated by (F-F0)/(FDNA-F0). F, fluorescence of 
polyplexes and ethidium bromide; F0, fluorescence of ethidium bromide only; FDNA, fluorescence 
of DNA and ethidium bromide (N=3, error bars represent standard deviation) 
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Figure 3.7: Heparan sulfate displacement assay of polymer/DNA polyplexes at 2:1 weight-to-
weight ratio. D.PEIs were incubated at 37 oC for 0, 24, 72, and 192 hours before complexed with 
DNA. (A) unmodified 25 kDa PEI, (B) unmodified 800 Da PEI, (C-F) 48 kDa D.PEI, (G-J) 6.2 
kDa D.PEI, (K-N) 1.2 kDa D.PEI. The polymer to DNA weight-to-weight ratio for each polyplex 
formation is listed above the corresponding lane 
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Figure 3.8: In vitro transfection of HeLa cells with polyplexes formed with pGL3 and unmodified 
25 kDa PEI or D.PEIs at various polymer:DNA weight-to-weight ratios (t-test: †, p<0.01; ‡, 
p<0.01; *, p<0.01). Luciferase expression in the cell lysates is reported as relative light unit 
(RLU) normalized by the total amount of protein the cell lysates (N=4, error bars represent 
standard deviation). 
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Figure 3.9: In vitro transfection of MDA-MB-231 cells with polyplexes formed with pGL3 and 
unmodified 25 kDa PEI or D.PEIs at various polymer:DNA weight-to-weight ratios (t-test: †, 
p<0.01; ‡, p<0.01; *, p=0.16). Luciferase expression in the cell lysates is reported as relative 
light unit (RLU) normalized by the total amount of protein the cell lysates (N=4, error bars 
represent standard deviation).  
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Figure 3.10: Cytotoxicity of biodegradable PEI derivatives reported as normalized metabolic 
activity in HeLa cell line in the presence of varying amounts of unmodified 25 kDa PEI and 
D.PEIs (ANOVA: †, 48 kDa D.PEI, p<0.05; ‡, 6.2 kDa D.PEI, p<0.05; *, 1.2 kDa D.PEI, p<0.05). 
Metabolic activity was normalized to control with no polymer present (N=6, error bars represent 
standard deviation). 
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Figure 3.11: Cytotoxicity of biodegradable PEI derivatives reported as normalized metabolic 
activity in MDA-MB-231 cell line in the presence of varying amounts of unmodified 25 kDa PEI 
and D,PEIs (ANOVA: †, 48 kDa D.PEI, p<0.05; ‡, 6.2 kDa D.PEI, p<0.05; *, 1.2 kDa D.PEI, 
p<0.05). Metabolic activity was normalized to control with no polymer presence (N=6, error bars 
represent standard deviation). 
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Figure 3.12: Cellular uptake of fluorescently labeled polyplexes with YOYO-1 intercalated pGL3 
in HeLa cells (t-test: †, p<0.01). Results are reported as median fluorescence normalized by 
control with no polymer present using FACS (N=3, error bars represent standard deviation). 
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Figure 3.13: Cellular uptake of fluorescently labeled polyplexes with YOYO-1 intercalated pGL3 
in MDA-MB-231 cells (t-test: †, p<0.01; ‡, p<0.01; *, p<0.01). Results are reported as median 
fluorescence normalized by control with no polymer present using FACS (N=3, error bars 
represent standard deviation). 
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Chapter 4 
Discussion, Conclusions, and Future Work 
4.1 Discussion 
Safety and efficacy are, quite simply, the most important factors in gene therapy. Compared to 
viruses, non-viral gene delivery vectors such as polymers and lipids are safer alternatives, but 
they display much lower efficiency and higher cytotoxicity. Much research has been done in 
optimizing polymers and lipids as potential delivery vehicles by chemically modifying their 
structures or by conjugating ligands onto their surfaces [1-3]. Specifically, the addition of 
degradable cross-linker in PEI has been extensively investigated in order to reduce the 
cytotoxicity and increase the transfection efficiency of PEI [4-5, 7]. Instead of synthesizing PEI 
derivatives with new cross-linkers and chemistry, we have further characterized and optimized 
the PEI derivatives first reported by Forrest et al. due to their relatively simple chemistry and 
efficient gene transfer [5]. 
Utilizing a heterogeneous PVP-supported Fe(III) catalyst, we synthesized a set of three D.PEIs 
with a wide range of molecular weights (1.2-48 kDa) through Michael addition between 800 Da 
PEI and 1,6-hexanediol diacrylate, resulting in D.PEIs with about a 15% cross-linking density 
(Table 3.2). NMR has confirmed the presence of ester linkages in each D.PEI and the 
degradation of the D.PEI when incubated at 37oC (Figure 3.2, 3.3, and 3.4). Both gel 
retardation and ethidium bromide exclusion studies indicated that all the D.PEIs are able to bind 
to DNA as tightly as unmodified 25 kDa PEI (Figure 3.5 and 3.6). At their optimal transfection 
ratios, the D.PEI polyplexes are ~1.4-fold larger than the unmodified 25 kDa PEI polyplexes 
before incubation, probably due to aggregation and the fact that the optimal D.PEI/DNA ratios 
for transfection are about 7-12-fold higher than that of 25 kDa PEI (Table 3.3). However, after 4 
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hours incubation, which simulates the 4 h exposure of polyplexes to DMEM during transfection, 
the polyplexes reached approximately the same size between D.PEIs and 25 kDa PEI, except 
for 1.2 kDa D.PEI polyplexes. This indicates that during transfection, the polyplexes swelled to 
similar size, making it unlikely that polyplex size plays a major factor in the improved 
transfection efficiency of the D.PEIs. 
All three D.PEIs have demonstrated about 2-5-fold better transfection efficiency than unmodified 
25 kDa PEI, in both HeLa and MDA-MB-231 cell lines, at their respective optimized transfection 
ratios (Figure 3.8 and 3.9). In particular, the higher molecular weight D.PEIs, 48 kDa and 6.2 
kDa, consistently transfect better than 1.2 kDa D.PEI in both cell lines, which is in agreement 
with findings that suggest improved transfection efficiency with increasing PEI molecular weight 
[6]. However, the fact that 48 kDa D.PEI needs about 5-7-fold more polymer in order to transfect 
better than unmodified 25 kDa PEI indicates that in addition to molecular weight, there are other 
factors that contribute to the D.PEIs‟ improved transfection efficiency, likely involving 
cytotoxicity, cellular uptake, and DNA unpackaging. 
Additionally, we have demonstrated the D.PEIs possess much lower cytotoxicity than 
unmodified 25 kDa PEI. D.PEIs show almost no toxic effect in MDA-MB-231 cells; 48 kDa and 
6.2 kDa D.PEIs show about 50% viability, while 1.2 kDa D.PEI shows no toxic effect, in HeLa 
cells at 50 g polymer/mL (Figure 3.10 and 3.11). The optimal transfection ratio for 25 kDa PEI 
is 2:1 g polymer/g DNA, which is approximately equal to a concentration of 2 g polymer/mL. 
This concentration corresponds to about 60% and 80% viability for HeLa and MDA-MB-231 cell 
lines. Unlike unmodified PEI, our D.PEIs show above 80% viability in HeLa cells and almost no 
toxicity in MDA-MB-231 cells at their respective optimal transfection ratios. These results 
partially explain why, as we increased the amount of polymers used to complex with DNA, the 
transfection efficiency improved for D.PEI but regressed for unmodified PEI. 
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As discussed previously, cellular uptake and DNA unpackaging are two important aspects of 
gene delivery. Polyplexes must be able to enter the cell and release their DNA in order for the 
DNA to travel across the nuclear membrane or to be transcribed. HeLa cells show 
approximately the same cellular uptake for both unmodified PEI and D.PEIs, except for 48 kDa 
D.PEI, while MDA-MB-231 cells show 2-7-fold higher uptake of D.PEIs than unmodified PEI 
(Figure 3.12 and 3.13). The significant difference in cellular uptake between D.PEIs and 
unmodified PEI in MDA-MB-231 cells is in good agreement with the gene transfer trend we 
observed in the same cells. However, this is not the case for HeLa cells, where there is no 
discernible difference in uptake to correlate with the increase in transfection. To explain this 
discrepancy, we investigated the polymer‟s ability in unpackaging DNA through heparan sulfate 
competitive displacement assay. At the same polymer:DNA weight-to-weight ratio, D.PEIs show 
they more readily dissociate from DNA than unmodified 25 kDa PEI in the presence of heparan 
sulfate (Figure 3.5), which likely contributes to the increase in transfection efficiency for D.PEIs 
in both HeLa and MDA-MB-231 cells. These results show that gene delivery is a dynamic 
process where one must take various cellular barriers into account when designing potential 
non-viral gene delivery vectors. 
Compared to the biodegradable PEI study first reported by Forrest et al. [5], this present work 
has further characterized the D.PEI and investigated the effects of molecular weight on D.PEI‟s 
gene delivery. Forrest et al. synthesized 14kDa and 30 kDa biodegradable PEIs by cross-linking 
1,3-butanediol diacrylate and 1,6-hexanediol diacrylate, respectively, using 800 Da PEI without 
heterogenous catalyst and under different reaction conditions than that reported here. Forrest et 
al. showed that their D.PEIs were capable of condensing DNA, maintained reduced toxicity, and 
improved transfection efficiency in different cell lines but were unable to make any conclusive 
remarks on why their D.PEIs are more effective than the 25 kDa control or the effect of D.PEI‟s 
molecular weight on gene transfer abilities. However, in this current report, we synthesized 
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D.PEIs with a wide range of molecular weights, which has allowed us to correlate D.PEI‟s 
molecular weight with various gene delivery properties of cross-linked PEI. Specifically, we are 
able to explain the improved transfection efficiency through the differences between D.PEIs and 
unmodified PEI in terms of molecular weight, cytotoxicity, polyplex internalization, and DNA 
unpackaging ability. 
As mentioned in the Introduction, several groups have reported various diacrylate cross-linked 
PEIs and show at least 50-fold improvement in transfection efficiency and reduced cytotoxicity 
compared to the controls [8-11]. However, it is difficult to draw a direct comparison between 
those polymers and the polymers reported here, mainly due to the use of different cells and 
controls. In addition, many of those reports only studied how the size, degradability, and 
cytotoxicity of the cross-linked PEI polyplexes affect transfection but neglect the effects of 
intracellular barriers on gene delivery, namely cellular uptake and DNA unpackaging of the 
polyplexes. Without this characterization information, it is impossible to fully understand or 
compare any cross-linked PEIs as polymeric gene delivery vectors and to explain relative 
enhancement in gene transfer ability. 
4.2 Conclusions and Future Work 
We reported here a controllable synthesis of biodegradable PEI by cross-linking 800 Da PEI 
and 1,6-hexanediol diacrylate through the use of a polymer-supported heterogeneous catalyst. 
The resulting polymers have a wider range of molecular weights and have demonstrated 
several fold more efficient gene transfer compared to commercially available, unmodified, 25 
kDa PEI. The improvement in gene delivery of these D.PEIs is likely due to some combination 
of their low cytotoxicity, easy DNA unpackaging, and high cellular uptake.  
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Future studies should examine the intracellular trafficking mechanisms of D.PEIs in both of the 
cell types utilized in the present study. This will enable us to understand the fundamental 
cellular behaviors driving the improved performance of our D.PEIs in order to optimize the 
design of future PEI-based materials. Specifically, we will investigate the D.PEIs‟ cellular 
uptake, such as clathrin- or caveolin-mediated pathways, by utilizing appropriate targeting 
ligands and drugs. Additionally, we will study the effect of endosomal escape by disrupting the 
endosome and observe any effects on the D.PEIs‟ gene transfer abilities. Pending the success 
of this additional in vitro characterization, we may then proceed to in vivo testing due to the 
enormous therapeutic promise of our described D.PEIs  
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